Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

bioage labs inc - BIOA

BIOA

Close Chg Chg %
22.16 0.00 0.00%

Open Market

22.16

0.00 (0.00%)

Volume: 25.54K

Last Updated:

Jul 17, 2026, 9:45 AM EDT

Trade Now

Company Overview: bioage labs inc - BIOA

BIOA Key Data

Open

$21.36

 Day Range

21.36 - 22.16

52 Week Range

4.11 - 25.96

 Market Cap

$985.07M

Shares Outstanding

44.45M

 Public Float

31.67M

Beta

0.62

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.41

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

737.42K

  

BIOA Performance

1 Week
 
 -8.96%
 
1 Month
 
 6.69%
 
3 Months
 
 19.85%
 
1 Year
 
 378.62%
 
5 Years
 
 N/A
 

BIOA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About bioage labs inc - BIOA

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

BIOA At a Glance

BioAge Labs, Inc.
5885 Hollis Street
Emeryville, California 94608
Phone 1-510-806-1445 Revenue 9.00M
Industry Biotechnology Net Income -80,605,000.00
Sector Health Technology Employees 62
Fiscal Year-end 12 / 2026
View SEC Filings

BIOA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 52.851
Price to Book Ratio 1.818
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.159
Enterprise Value to Sales 22.218
Total Debt to Enterprise Value 0.028

BIOA Efficiency

Revenue/Employee 145,080.645
Income Per Employee -1,300,080.645
Receivables Turnover 4.568
Total Asset Turnover 0.028

BIOA Liquidity

Current Ratio 14.241
Quick Ratio 14.241
Cash Ratio 13.959

BIOA Profitability

Gross Margin 97.632
Operating Margin -1,031.462
Pretax Margin -896.109
Net Margin -896.109
Return on Assets -24.657
Return on Equity -27.086
Return on Total Capital -29.035
Return on Invested Capital -26.868

BIOA Capital Structure

Total Debt to Total Equity 2.044
Total Debt to Total Capital 2.003
Total Debt to Total Assets 1.881
Long-Term Debt to Equity 0.856
Long-Term Debt to Total Capital 0.839
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bioage Labs Inc - BIOA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - 8.99M
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
129.00K 162.00K 167.00K 213.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
129.00K 162.00K 167.00K 213.00K
Depreciation
129.00K 162.00K 167.00K 213.00K
Amortization of Intangibles
- - - -
-
COGS Growth
- +25.58% +3.09% +27.54%
Gross Income
(129.00K) (162.00K) (167.00K) 8.78M
Gross Income Growth
- -25.58% -3.09% +5,358.68%
Gross Profit Margin
- - - +97.63%
-
2022 2023 2024 2025 5-year trend
SG&A Expense
39.84M 48.24M 78.03M 101.56M
Research & Development
30.52M 33.89M 59.04M 73.97M
Other SG&A
9.32M 14.35M 18.99M 27.60M
SGA Growth
- +21.08% +61.75% +30.16%
Other Operating Expense
- - - -
-
Unusual Expense
(23.00K) 10.09M 177.00K 214.00K
EBIT after Unusual Expense
(39.95M) (58.49M) (78.37M) (92.99M)
Non Operating Income/Expense
465.00K 2.43M 9.63M 13.09M
Non-Operating Interest Income
465.00K 2.43M 9.63M 13.09M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
241.00K 7.79M 2.37M 697.00K
Interest Expense Growth
- +3,134.02% -69.63% -70.55%
Gross Interest Expense
241.00K 7.79M 2.37M 697.00K
Interest Capitalized
- - - -
-
Pretax Income
(39.72M) (63.85M) (71.11M) (80.61M)
Pretax Income Growth
- -60.75% -11.36% -13.35%
Pretax Margin
- - - -896.11%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(39.72M) (63.85M) (71.11M) (80.61M)
Minority Interest Expense
- - - -
-
Net Income
(39.72M) (63.85M) (71.11M) (80.61M)
Net Income Growth
- -60.75% -11.36% -13.35%
Net Margin Growth
- - - -896.11%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(39.72M) (63.85M) (71.11M) (80.61M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(39.72M) (63.85M) (71.11M) (80.61M)
EPS (Basic)
-1.1626 -1.8672 -1.9835 -2.2432
EPS (Basic) Growth
- -60.61% -6.23% -13.09%
Basic Shares Outstanding
34.17M 34.20M 35.85M 35.93M
EPS (Diluted)
-1.1626 -1.8672 -1.9835 -2.2432
EPS (Diluted) Growth
- -60.61% -6.23% -13.09%
Diluted Shares Outstanding
34.17M 34.20M 35.85M 35.93M
EBITDA
(39.84M) (48.24M) (78.03M) (92.57M)
EBITDA Growth
- -21.08% -61.75% -18.63%
EBITDA Margin
- - - -1,029.09%
-

Snapshot

Average Recommendation BUY Average Target Price 51.429
Number of Ratings 9 Current Quarters Estimate -0.65
FY Report Date 09 / 2026 Current Year's Estimate -2.557
Last Quarter’s Earnings -0.613 Median PE on CY Estimate N/A
Year Ago Earnings -2.24 Next Fiscal Year Estimate -1.878
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 9 9 10
Mean Estimate -0.65 -0.70 -2.56 -1.88
High Estimates -0.46 -0.50 -2.12 1.15
Low Estimate -0.88 -0.96 -3.04 -3.02
Coefficient of Variance -20.46 -22.06 -12.97 -70.07

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 5
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Overweight

Insider Actions for Bioage Labs Inc - BIOA

Date Name Shares Transaction Value
Feb 20, 2026 Dov A. Goldstein Chief Financial Officer 110,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Paul D. Rubin Chief Medical Officer 110,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Shane Barton Principal Accounting Officer 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Kristen Fortney Chief Executive Officer; Director 330,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Eric Morgen Chief Operating Officer; Director 110,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Eric Morgen Chief Operating Officer; Director 12,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 16, 2026 Dov A. Goldstein Chief Financial Officer 40,434 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $18.43 per share 745,198.62
Jan 16, 2026 Dov A. Goldstein Chief Financial Officer 35,994 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $19.45 per share 700,083.30
Jan 16, 2026 Dov A. Goldstein Chief Financial Officer 24,331 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.54 per share 499,758.74
Jan 16, 2026 Dov A. Goldstein Chief Financial Officer 22,408 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.08 per share 472,360.64
Jan 16, 2026 Dov A. Goldstein Chief Financial Officer 92,587 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 12, 2025 Paul D. Rubin Chief Medical Officer N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12 per share 0.00
Dec 12, 2025 Paul D. Rubin Chief Medical Officer 9,383 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Bioage Labs Inc in the News